KRAS and non-small cell lung carcinoma: Preliminary clinical data of olomorasib have reported an ORR of 60% and a favorable safety profile with absence of high-grade liver toxicity in patients with treatment-naïve KRAS G12C NSCLC [29] (NCT04956640) and have subsequently prompted the phase III trial SUNRAY-01 studying its combination with pembrolizumab with or without platinum-based chemotherapy based on PD-L1 expression level as the first-line treatment in patients with KRAS G12C-mutant advanced NSCLC (NCT06119581) [30].